MedTrace Logo

Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities

NCT07690579 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2026-07-08

No results posted yet for this study

Summary

Prostate Cancer (PC) is the most common non-cutaneous malignancy diagnosed and second leading cause of cancer death among men across the United States. PC among Black men accounts for a higher proportion alike of cancer diagnoses and deaths. In the prostate specific antigen (PSA)-based screening era, mortality rates improved at a similar velocity among Black and White men, but the 2- to 3-fold excess mortality burden borne by Black men has persisted over the past 40 years, the second highest among all major cancers. In recent years mortality is rising among Black men, and at a rapid velocity.

The explanations for this disparity-the extent to which it is attributable to genetics, environmental factors including Structural and Social Determinants of Health (SSDH), or access to care-are multifactorial and have been elucidated to a limited extent. A large meta-analysis recently found that across dozens of studies and cohorts, greater adjustment for clinical and SSDH factors generally resulted in race itself dropping as a significant predictor.

These and other findings suggest that the determinants of disparity be identified at time of, and prior to, cancer diagnosis, and that both genetic and environmental factors contribute to earlier development and progression.

Conditions

Interventions

OTHER

Questionnaires

Participants will receive surveys to complete online via a secure system.

OTHER

Medical Record Review

Data will be collected from participants medical charts which includes disease history, pathological findings, and other disease characteristics.

Sponsors & Collaborators

Principal Investigators

  • Matthew Cooperberg, MD · University of California, San Francisco

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2028-03-31
Completion
2028-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07690579 on ClinicalTrials.gov